T HE PREVALENCE OF DIABETES IS
increasing at an alarming rate, as are the associated personal and societal costs. While diabetes care should address a number of risk factors (dyslipidemia, blood pressure, tobacco use, etc), hyperglycemia itself not only defines the disease but is the cause of its most characteristic symptoms and long-term complications. Good glycemic control reduces the incidence and progression of microvascular disease in both type 1 and 2 diabetes. [1] [2] [3] [4] The impact of hyperglycemia on cardiovascular disease is also becoming increasingly evident. [5] [6] [7] Although the Diabetes Control and Complications Trial found an increased incidence of hypoglycemia accompanying intensive glycemic control, 8 participants rated their overall quality of life as improved by better glycemic control. 9 Assessing glycemia in diabetes, however, has always been a challenge. Until about 1910, overt symptoms of hyperglycemia were the only available metric of diabetic control. 10 The development of urine glucose testing allowed documentation of severe hyperglycemia, but was seriously limited by being only semiquantitative, retrospective, and significantly affected by urine concentration. An important change in diabetes care occurred in the 1970s and 1980s as 2 methods became available: selfmonitoring of blood glucose (SMBG) and hemoglobin A 1c (HbA 1c ) testing. Home urine testing became obsolete except when testing for ketones in situations of suspected ketoacidosis.
The information derived from these 2 assessment tools is fundamentally different. SMBG reveals the immediate, hour-to-hour blood glucose, which in people without diabetes varies only about 50% throughout the normal day but may vary 10-fold in patients with diabetes. Long-term or month-tomonth glycemia is assessed by HbA 1c . In this review, we summarize the theoretical and methodological basis, standardization and confounders, evidence of clinical utility and controversies, and recommendations for use of SMBG and HbA 1c . We also describe important advances coming in the near future. In limiting the number of articles evaluated, preference was given to larger cohort studies, randomized trials (especially those that enrolled Ն100 patients), prior comprehensive reviews, metaanalyses, quality of peer-reviewed publications, and published guidelines.
METHODS

EVIDENCE SYNTHESIS
Self-monitoring of Blood Glucose
With a small fingerprick and a microliter or less of blood, people with diabetes can know their blood glucose level at any time. This allows patients to relate events in their daily life and treatment regimen to glycemic results. The introduction of SMBG thus caused a shift in the focus of diabetes management from the physician's office into the hands of the patient. Given proper understanding and communication with the health care professional, patients could, to an extent previously unheard of, take control of their own diabetes.
Current glucose monitors use glucose test strips impregnated with glucose oxidase, glucose dehydrogenase, or hexokinase to convert blood glucose into gluconic acid and hydrogen peroxide when a drop of blood is added to the strip. This reaction is then quantified by various means including colorimetric methods, reflectance photometry, absorbance photometry, and electrochemistry.
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Standardization and Confounders. In general, results from glucose meters are not as accurate as those from laboratory methods, although they are far more accurate than the earlier approach of visual matching to colors. While standards for acceptable accuracy vary, the International Organization for Standardization (http://www.iso.org) recommends that more than 95% of readings be within 15 mg/dL (0.83 mmol/L) for glucose readings that are less than 75 mg/dL (4.2 mmol/L), and within 20% for higher blood glucose values when compared with the standard YSI 2700 reference method (Yellow Springs Instruments, Yellow Springs, Ohio). Under optimal circumstances, many meters meet these accuracy standards 12 ; however, there are confounding variables.
Operator-related errors are a more significant source of error than are instrument-related errors. 13 A significant between-patient variance has been reported in glucose meter readings, 14 although the role of education in reducing user inaccuracies was demonstrated in a before-after study of 280 patients by Bergenstal et al. 15 Patient failure to calibrate the glucose meter regularly is a common cause of error. 12 Other common technique errors include improper use of control solutions, poor hand washing, and dirty meters. 12 Improper storage of test strips, which exposes them to humidity or excessive temperature, can falsely elevate results. 15 Certain drugs, such as ascorbic acid, acetaminophen, dopamine, and mannitol, can affect the accuracy of some meters. 16 Glucose meters are also less reliable in the lower ranges of glycemia 17 and may overestimate true glucose values in the high glycemic range.
14 A low hematocrit increases SMBG results 18 because of the lower erythrocyte mass. Erythrocytes are relatively glucopenic, so the whole blood applied to strips normally has about 15% less glucose than plasma glucose, the difference lessened with anemia. Most meters today are calibrated to provide plasma glucose equivalent readings 19 and assume a normal hematocrit.
To reduce pain and promote more frequent testing, blood may be drawn from sites other than the fingertips, such as the forearm and thigh. This alternate site testing is a good option for routine SMBG testing before meals but may lead to false results after eating, exercising, or with insulin treatment.
20,21 For example, compared with finger blood, forearm blood glucose appears to rise more slowly and less high after a small meal, whereas after exercise, thigh and forearm glucose levels fall lower than does fingertip glucose. Therefore, fingertip testing is preferred in circumstances of rapidly changing blood glucose levels.
Clinical Utility and Controversies. The age-adjusted percentage of adults with diabetes performing daily SMBG increased from 36% in 1994 to 58% in 2003. 22 Frequency of SMBG varies directly with the intensity of treatment, 23 and cost inhibits its use, 24 either insured or out-of-pocket. 25 Early nonrandomized reports of SMBG were positive. [44] [45] [46] Four Veterans Administration studies, however, each reported no benefit to SMBG, [47] [48] [49] [50] although 6 of the 10 other retrospective or cross-sectional studies 23, [44] [45] [46] [51] [52] [53] [54] [55] [56] did show benefit. A large cohort study of a managed care population of 24 000 patients found SMBG improved HbA 1c by up to 1%. 23 A Canadian crosssectional study found patients who were insured for SMBG had significantly lower HbA 1c levels than those without coverage, 52 and a study of 115 patients found that HbA 1c was not affected by simply prescribing SMBG. 53 Tapping National Health and Nutrition Examination Survey (NHANES) data cross-sectionally, Harris found more SMBG among insulin-treated people, but no relationship between frequency of HbA 1c and SMBG 54 ; Blonde et al disputed this finding. 55 A recent evaluation from Italy found no effect of SMBG in people with type 2 diabetes not taking insulin, 56 consistent with their previous emphasis on the need for an educational link to SMBG. 57 RCTs have had more positive results, including all 6 of those studying more than 100 participants (Table) . Kwon et al randomly assigned 110 patients to usual care or Internet-based evaluation of SMBG, finding that with rapid feedback, SMBG proved beneficial. 28 Guerci et al in the AutoSurveillance Intervention Active (ASIA) trial studied patients in 265 French physicians' offices, finding small but significant benefit from SMBG. 36 Schwedes et al, in a German RCT of non−insulintreated patients, found improved HbA 1c with SMBG. 35 A recent smaller study by Davidson et al stands out as a negative RCT. It found no effect of pre-and postprandial SMBG in 89 community clinic, non−insulin-treated participants of predominantly low socioeconomic status in Los Angeles, with educators blinded to group assignment. 37 Two systematic reviews and 2 metaanalyses were reviewed (Table) , all of people with non-insulin-treated diabetes. Faas, in 1997, noted no significant evidence of benefit in type 2 diabetes, but recommended more studies. 38 The meta-analysis by Coster et al of 285 patients also found that blood or urine monitoring had nonsignificant effect. 39 The 2 most recent reports, however, were positive. Sarol et al, summarized 8 RCTs of 1307 patients, and found a significant reduction in HbA 1c of approximately 0.4% among patients who performed SMBG. 40 Welschen et al recently reviewed the literature for noninsulin-using people with diabetes, concluding that SMBG does have a favorable effect on HbA 1c, 41 although in a counterpoint, Davidson disputed the conclusion.
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In sum, the larger, more recent trials reviewed in this article support the conclusion that SMBG, if effectively translated into action, improves glycemia. The data are most conclusive for insulin-using people, in whom SMBG as part of a complete regimen to improve glycemia does reduce long-term complications of diabetes. 1 The evidence that links SMBG to improved glycemia in non-insulin-requiring type 2 diabetes is less definitive.
Recommendations for Use. Consistent communication between the patient and health care professional is essential to effective implementation of self-monitoring and maintenance of patient motivation. When patients monitor regularly, they should be taught how to act immediately on the results as well as communicate the results to the health care professional. The health care professional must in turn take note of and evaluate results, communicate treatment modifications based on the results, and include follow-up.
There are no definitive clinical studies on optimal frequency of SMBG, so this is best decided by the individual patient and clinician. The American Diabetes Association (ADA) recommends SMBG 3 or more times daily for type 1 diabetes and no specific frequency is recommended for type 2.
58 It is reasonable to recommend more frequent SMBG in people with more unstable glycemia, those prone to hypoglycemia, and when treatment changes are made. We believe that glycemic goals should be individualized, but the ADA has recommended that adults with type 1 or 2 diabetes aim for preprandial plasma glucose between 90 and 130 mg/dL (5.0-7.2 mmol/L) and peak postprandial plasma glucose less than 180 mg/dL (Ͻ10 mmol/L).
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The optimal timing of SMBG testing also remains controversial. Monnier et al have made the most detailed analyses of this issue. 59, 60 They found that the "extended post-lunch" (5 PM) values predicted HbA 1c less than 7% with better sensitivity and specificity than did fasting glucose. But in less wellcontrolled type 2 patients, a 3-point daily testing system was optimal, one fasting (8 AM), one postprandial (10 AM), and one postabsorptive (5 PM). In people with type 1 diabetes, a 4-to 8-point daily system was recommended. In another study, peak postlunch blood glucose values did not affect HbA 1c after controlling for mean glycemia. 61 In diabetic pregnancy, when the object is to approach euglycemia for the benefit of the developing fetus, postprandial testing has proven efficacy for both women with pregestational type 1 diabetes 62 and women with gestational diabetes. 63 Epidemiologic studies suggest that postprandial hyperglycemia is more predictive of adverse cardiovascular outcomes, 64 A consensus panel concluded that evidence is not adequate to support routine postprandial blood glucose testing. 66 Uncertainty about exact timing postprandially and exact meal content were cited. Our practice is to rely on fasting, preprandial, and bedtime SMBG unless there is a special circumstance such as an unexplained discrepancy between HbA 1 c and SMBG results, pregnancy, or mild glucose intolerance. Also, given the potential seriousness of nocturnal hypoglycemia, 67 it is clinically indicated to test in the middle of the night if patients have any symptomatic evidence of nighttime lows and to make appropriate treatment adjustments.
Patients using insulin pumps are a subgroup with special need for frequent blood glucose monitoring, both to guide their bolus insulin dosing and because if insulin delivery is inadvertently interrupted, they become insulinopenic very rapidly and ketoacidosis can develop quickly. 68 SMBG can be used most effectively by using data management features available on the glucose meter to calculate means, variance, and trends by time-ofday or over weeks and months. Most meters can now easily download results into a personal computer, so managed data (graphs, averages) can be quickly printed. The only requirements are that the time and date be correctly entered into the meter, and that the office have a connecting cable and simple software. Examples of such downloads are in FIGURE 1 and FIGURE 2 . In our opinion, this data management capability is useful and underutilized.
The Future: Continuous Glucose Monitoring. Continuous glucose monitoring (CGM) is in its infancy as a practical clinical tool, but it is likely to change diabetes management. Moving from intermittent SMBG to CGM is a conceptual as well as a technical advance. With CGM, the continuous, sometimes extreme fluctuations of blood glucose are readily apparent. Alarms can be set to alert patients of high or low blood glucose concentrations. The immediate effect of every dietary and therapeutic intervention can be seen. At present, there are several CGM products on the market and more are under development. 69 These monitors measure glucose concentration in subcutaneous interstitial fluid, which can reflect changes in blood glucose concentrations reasonably quickly. 70, 71 Recent reports describe the use of CGM in clinical and research settings, [72] [73] [74] but the monitors are not easily used on a routine, clinical, long-term basis. Spectroscopy-based 75 and fluorescence-based sensors, 76 which could be entirely noninvasive, have been slow to develop.
The ultimate goal of CGM is to drive a closed-loop insulin delivery system, the "artificial pancreas." 77 This goal, in early stages of development, depends on the sensors being robust, accurate, and easy to use.
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Hemoglobin A 1C
In the late 1960s, a minor component of human hemoglobin A was noted to be increased in patients with diabetes. 78 By the mid-1970s, HbA 1c was shown to decrease as glycemic control improved, and thus, the potential of HbA 1c as a clinical and research tool was recognized. 79 Over the last 25 years, HbA 1c testing has come into common use, serving as a convenient method for evaluating average glycemia over the previous several months.
HbA 1c is defined as the stable adduct of glucose at the N-terminal amino group of the ␤-chain of hemoglobin Ao (N-[1-deoxyfructosyl]hemoglobin). 80 It forms as a posttranslational modification, in which glucose condenses with the free amine group on the Nterminal valine residues of the hemoglobin ␤-chain. The resulting Schiff base is unstable and undergoes an irreversible Amadori rearrangement to form a stable ketoamine. 81 Glycation also occurs at certain lysine residues on the hemoglobin ␣-and ␤-chains; total glycohemoglobin or total glycated hemoglobin refer to measurement of these products as well as HbA 1c . Glycated hemoglobin is quantified most commonly with methods that distinguish it from nonglycated hemoglobin on the basis of either charge (cationexchange chromatography, electrophoresis, isoelectric focusing) or structural characteristics (affinity chromatography, immunoassays). 82 A direct relationship exists between HbA 1c and mean glycemia because erythrocytes are continuously glycated during their 120-day lifespan and the rate of glycohemoglobin formation is proportional to the ambient glucose concentration. In the Diabetes Control and Complications Trial, an HbA 1c of 6% (measured by ion-exchange highperformance liquid chromatography) corresponded to a mean plasma glucose level of 135 mg/dL (7.5 mmol/L), and each 1% increase in HbA 1c corresponded to an increase in mean plasma glucose level of approximately 35 mg/dL (2 mmol/L). 83 One caveat in interpreting the linearity of this relationship is that HbA 1c does not reflect blood glucose levels equally over the previous 120 days. Rather, recent changes in glycemic control are overrepresented in HbA 1c . About 50% of HbA 1c is determined by glycemia during the 1 month preceding the measurement, 25% from the 30 to 60 days before the measurement, and 25% from the 60 to 120 days prior to the measurement. 84 
Standardization and Confounders.
Comparing study results and setting HbA 1c goals assumes reliability and comparability of methods. In the early 1990s, there were over 20 available methods, with widely varying reference ranges. The National Glycohemoglobin Standardization Program (NGSP) (http://www.missouri.edu /~diabetes/ngsp.html) was created to remedy this situation and has been highly successful. Currently, 99% of laboratories in the United States use certified assays that are traceable to the Diabetes Control and Complications Trial glycohemoglobin reference (ionexchange high-performance liquid chromatography) with a total imprecision (coefficient of variation) of 4% or less. 88 as has the NGSP Web site.
Many conditions also exist that alter HbA 1c levels independent of the assay method. Any process that shortens erythrocyte lifespan decreases HbA 1c , since glycation increases with age of the red cell. Kidney disease, liver disease, hemolytic anemia, hemoglobinopathies, and recovery from blood loss will all decrease HbA 1c on this basis. Vitamins C and E have been reported to lower HbA 1c measurements, possibly by inhibiting glycation. 89, 90 Lower HbA 1c levels are found in diabetic and nondiabetic pregnant women, probably due both to lower fasting blood glucose and a shortened erythrocyte lifespan, prompting a proposal for lowering the upper normal limit for HbA 1c in pregnancy. 91 Iron-deficiency anemia, on the other hand, has been associated with increased HbA 1c . 92 Any process that slows erythropoesis, such as aplastic anemia, will increase HbA 1c by causing an older erythrocyte cohort.
We studied whether glycemic lability, independent of mean glycemia, af-fects HbA 1c . Analyzing the SD of blood glucose in patients performing frequent SMBG, we found that after controlling for mean glycemia, HbA 1c is not affected by glycemic lability. 93 Another report reached a similar conclusion on glycemia after lunch.
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Clinical Utility and Controversies. The measurement of HbA 1c has been the primary index of glycemia in the Diabetes Control and Complications Trial, the United Kingdom Prospective Diabetes Study, and many other studies. It is therefore the basis upon which glycemic control is known to be a mediator of diabetic complications. The Diabetes Control and Complications Trial reduced mean HbA 1c by 1.8% in the intensively treated group (7.3% vs 9.1%), and this difference resulted in a 76% (95% confidence interval [CI], 62%-85%) decrease in the development of new retinopathy, a 39% (95% CI, 21%-52%) reduction in microalbuminuria, and a 60% (95% CI, 38%-74%) decrease in the development of clinical neuropathy. 1 Similarly, in type 2 diabetes, the United Kingdom Prospective Diabetes Study found a 25% (95% CI, 7%-40%) decrease in microvascular complications associated with the 10% reduction in HbA 1c achieved in the intensively treated group.
3 Surprisingly, the relatively short period of intensive control imposed in the Diabetes Control and Complications Trial has now been shown to have longlasting beneficial effects years after the HbA 1c levels of the groups merge.
94,95
HbA 1c is also the accepted measure of long-term glycemia in the Framingham 65 prospective cohort study and the long-term follow-up study to the Diabetes Control and Complications Trial, 96 both of which have found a lower risk for macrovascular complications with improved glycemia.
While abundant evidence demonstrates that improved HbA 1c reduces the risk of complications, it is not clear whether regular assessment of HbA 1c itself improves diabetic control. Larsen et al more than 15 years ago did find in an RCT of 240 patients with type 1 diabetes that treatment decisions made using quarterly HbA 1c results were more successful in lowering future HbA 1c results than those based only on blood or urine glucose testing. 97 An outside analysis of the Diabetes Control and Complications Trial raised the theory that there are "fast glycators" who, independent of glycemia alone, may be at greater risk of diabetic complications. 98, 99 This theory is disputed, 100, 101 however, and most evidence supports the conclusion that HbA 1c correlates with complication risk because it reflects glycemia, not because it causes complications directly.
Recently, NGSP-certified rapid HbA 1c assays have become available, allowing office and home testing. Point-ofcare HbA 1c testing at the clinic visit gives patients immediate feedback and allows the physician to make timely therapy changes. RCT evidence suggests that point-of-care HbA 1c testing may be superior to central laboratory testing in decreasing HbA 1c levels in type 1 and type 2 diabetes. 102, 103 Benefits of home testing, including increased patient autonomy and self-knowledge, must be weighed against the possibility of misuse, misinterpretation, and avoidance of the regular medical care system. No evidence exists to evaluate home HbA 1c testing.
In addition to HbA 1c , 2 other longterm indicies of glycemia, fructosamine and 1,5 anhydroglucitol (1,5-AG), are available but less widely used. Fructosamine, the product of posttranslational glycation of serum proteins, predominantly albumin, provides a reflection of glycemia over a shorter time frame than does HbA 1c . The reliability of the fructosamine assay is variable, bringing into question its clinical utility. One study found the mean glycemia over a prior 2-week period was better predicted by HbA 1c than fructosamine. 104 Even as an adjunct to home blood glucose monitoring, weekly fructosamine testing did not improve HbA 1c levels. 105 Recently, the US Food and Drug Administration approved a measure of the 1,5-AG assay. This measures serum levels of a molecule that is excreted in the urine with competitive inhibition by glucose. Thus, glucosuria inhibits 1,5-AG reabsorption at the renal tubule level, 1,5-AG excretion increases, and the serum levels fall with hyperglycemia. One study found an increase in 1,5-AG within 2 weeks of initiating treatment in patients with poorly controlled type 2 diabetes before a change in HbA 1c was seen. 106 In another study of 76 patients with wellcontrolled type 2 diabetes, 1,5-AG levels correlated with the degree of daily glycemic excursion, despite similar HbA 1 c values among treatment groups. 107 The assay is marketed and could be useful as a marker of postprandial hyperglycemia, presumably because glycosuria ensues postprandially. Further studies are needed, however, to make a convincing case that 1,5-AG actually reflects postprandial hyperglycemia.
Recommendations. The relationship between control and complications is continuous, with no single glycemic threshold below which the risk of complications is sharply reduced or eliminated. 108 Furthermore, the risk of hypoglycemia increases with lower HbA 1c , at least in type 1 diabetes 8 (less clearly for type 2 diabetes 109, 110 ). Therefore, determining a glycemic target involves considering the individual riskbenefit ratio; there is no scientific basis for choosing a single, universal target HbA 1c .
The ADA currently recommends that patients with type 1 and 2 diabetes achieve HbA 1c levels less than 7%, 58 a level that confers a low risk of complications (eg, 9-year progression of rate of retinopathy Ͻ4% 111 ). In some circumstances, such as elderly patients or those prone to hypoglycemia unawareness, target HbA 1c should be adjusted upward, and some people with diabetes can achieve HbA 1c of 6.5% or less. Studies to determine the ideal frequency of HbA 1c testing are lacking, but expert opinion suggests twice-yearly testing in patients meeting goals and quarterly testing in patients not meeting goals or in whom therapy is changed.
SELF-MONITORED BLOOD GLUCOSE AND HEMOGLOBIN A 1C IN DIABETES
It remains controversial whether HbA 1c should be accepted as a means of screening or diagnosing diabetes. It would provide a simple laboratory test that does not require the patient to fast and is not greatly affected by diet or activity level of the previous few days. Proponents also point to improvements in assay standardization 112 that have improved sensitivity and specificity when compared with criterion standard oral glucose tolerance testing. Indeed, the specificity for detecting undiagnosed diabetes in one study was 97.4% for HbA 1c results 2 SDs above the mean (Ͼ6.1%). 113 At present, however, HbA 1c testing is not accepted for screening or diagnostic purposes.
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The Future of HbA 1c . The International Federation of Clinical Chemistry has developed a new, more specific reference method for measuring glycated hemoglobin. 114 Using mass spectroscopy and capillary electrophoresis, this method assays the glycation of valine residues on hemoglobin. With this more specific measurement, the International Federation of Clinical Chemistry reference range is about 1.3% to 1.5% lower than NGSP values. 115 The normal range would thus be approximately 2% to 4% rather than the present 4% to 6%, and all values in the diabetic range would be about 2% lower than we are used to. A strong correlation exists between the existing and the new assays, however, and a conversion equation has been developed. 115 It is likely that this new International Federation of Clinical Chemistry method will become the anchor for glycated hemoglobin assays worldwide, but debate is ongoing as to how the new results will be reported, and even what the new test will be called. Changing the HbA 1c reference range could cause confusion for professionals and the public alike, given the decades-long effort to educate people about the importance of measuring HbA 1c and the goal of maintaining HbA 1c at less than 7%. One study found that simply modifying HbA 1c reference ranges caused a deterioration in glycemic control in patients. 116 The new anchor could be converted to NGSPstandardized results and be reported in the familiar units. An alternative proposal is to conduct a large international trial, better establishing the exact relationship of the new results to mean blood glucose, and to change the name of the test from HbA 1c to mean blood glucose equivalent. With a new reference range, new targets, and a new name, the results could be reported in familiar plasma glucose values rather than as percent HbA 1c .
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SUMMARY
Management of glycemia in diabetes is crucially important to the prevention of both acute and long-term complications. The 2 fundamental approaches to assessment, SMBG and HbA 1c , provide fundamentally different but complementary information. Regular SMBG is to be encouraged, particularly in patients using insulin, although the frequency can vary widely dependent particularly on the glycemic stability of the patient and the need to follow treatment changes. HbA 1c , the criterion standard measure of chronic glycemic control and complication risk, should be measured every 3 to 6 months to assess the success of the treatment regimen. Changes in both approaches are ongoing but with proper control of glycemia, diabetes can be successfully managed.
Author Contributions: Dr Saudek had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. 
